Back to results
US 2019/0290619 A1Published application
Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
AssigneeBiohaven Pharmaceutical Holding Company Ltd.
InventorVladimir CORIC
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceutical compositions including the immunotherapeutic agents and glutamate modulating agents are also disclosed.
Claims13
A method of treating cancer by administering a combination therapy to a patient in need thereof comprising of an effective amount of riluzole and a checkpoint inhibitor.
Dependencies are inferred from the claim text.